MAY 0 9 2005

On learning that this correspondence is being deposited with the U.S. Postal service with sufficient postage as First Class Mail, in an envelope addressed to:
INS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA.

22313-1450, on the date shown below.

Dated: May 5, 2005

Signature: (Mary Jane Dipalma)

PUT

Docket No.: ASZD-P01-854

(PATENT)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

David Cladingboel

Application No.: 10/532223

Confirmation No.: Not Yet Assigned

Filed: April 6, 2005

Art Unit: Not Yet Assigned

For: CHEMICAL INTERMEDIATE

Examiner: Not Yet Assigned

## **INFORMATION DISCLOSURE STATEMENT (IDS)**

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed within three months of the U.S. filing date (37 CFR 1.97(b)(1)).

A copy of each reference on the PTO/SB/08 is attached.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

, #

Application No.: 10/532223 Docket No.: ASZD-P01-854

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-1945, under Order No. ASZD-P01-854.

Dated: May 5, 2005

Respectfully submitted,

David P. Halstead, Ph.D.

Registration No.: 44,735

ROPES & GRAY LLP One International Place

Boston, Massachusetts 02110-2624

(617) 951-7000

(617) 951-7050 (Fax)

Attorneys/Agents For Applicant

MAY 0 9 2005 08

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of

Complete If Known		
Application Number	10/532223	
Filing Date	April 6, 2005	
First Named Inventor	David Cladingboel	
Art Unit	Not Yet Assigned	
Examiner Name	Not Yet Assigned	
Attorney Docket Number	ASZD-P01-854	

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2</sup> ( if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

1

	FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> ( <i>if known</i> )	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
	ВА	WO-01/28992-A2	04-26-2001				
	BB	WO-02/083690-A1	10-24-2002				

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

	NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²		
	CA	Chapman et al., "Diffuoramination of Heterocyclic Ketones: Control of Microbasicity," J. Org. Chem. 63:1566-1570 (1998)			
	СВ	Chapman et al., "Nitrolysis of a Highly Deactivated Amide by Protonitronium. Synthesis and Structure of HNFX1," J. Org. Chem. 64:960-965 (1999)			
	СС	Dave et al., "Facile Preparation of 3,7-Diazabicyclo[3.3.0]octaine and 3,7,10Triheterocyclic [3.3.3]Propellane Ring Systems from 1,5-Diazacyclooctane 3,7-Derivatives <sup>1</sup> ," J. Org. Chem. 61:8897-8903 (1996)			
	CD	Paudler et al., "3,7-Disubstituted Octahydro-1,5-diazocines. Their Conversion into Tetrahydro-1,5-diazocines and into Ring-Contraced Products," J. Org. Chem 32:2425-2430 (1967)			
	CE	Paudler et al., "1,5-Bis(p-toluenesulfonyl)-3,7-Dihydroxyoctahydro-1,5-diazocine," J. Org. Chem. 31:277-280 (1966)			
	CF	Stetter et al., "Synthese des 1.3-Diaza-6-oxa-adamantans," Chem. Ber. 96(11):2827-2831 (1963)			

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Date	
Signature	Consid	dered

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.